Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.
Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW. Tantravahi SK, et al. Among authors: dao kh. Leuk Lymphoma. 2016 Oct;57(10):2441-4. doi: 10.3109/10428194.2016.1138295. Epub 2016 Feb 8. Leuk Lymphoma. 2016. PMID: 26752680 Free PMC article. Clinical Trial. No abstract available.
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. Sherbenou DW, et al. Among authors: dao kh. Blood. 2010 Oct 28;116(17):3278-85. doi: 10.1182/blood-2008-10-183665. Epub 2010 Jun 2. Blood. 2010. PMID: 20519627 Free PMC article.
Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.
Lachowiez C, Cook RJ, Hayes-Lattin B, Maziarz RT, Borate U, Traer E, Leonard J, Newell L, Dao KH, Meyers G. Lachowiez C, et al. Among authors: dao kh. Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):105-109. doi: 10.1016/j.hemonc.2019.01.002. Epub 2019 Mar 2. Hematol Oncol Stem Cell Ther. 2019. PMID: 30836091 Free article. Clinical Trial.
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.
Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH. Goff DJ, et al. Among authors: dao kh. Cell Stem Cell. 2013 Mar 7;12(3):316-28. doi: 10.1016/j.stem.2012.12.011. Epub 2013 Jan 17. Cell Stem Cell. 2013. PMID: 23333150 Free PMC article.
Genome sequence of Xenia2 a DV cluster phage that infects Gordonia rubripertincta.
Agaiby C, Ahmed M, Argueta A, Arrowood K, Barrier KP, Church MW, Connell CR, Dao KD, Dao KHT, Davenport MR, Edmondson MD, Estabrook MI, Gondhi S, Gonzalez P, Leduc F, Ma T, Mansoor A, Mansoor S, Mattley L, Meyer C, Nguyen L, Niaz E, Parker JM, Ross DC, Scott DM, Semryck B, Takla K, Tiramdas A, Upputuru SK, Pollenz RS. Agaiby C, et al. Among authors: dao kht. Microbiol Resour Announc. 2024 Sep 10;13(9):e0057824. doi: 10.1128/mra.00578-24. Epub 2024 Aug 20. Microbiol Resour Announc. 2024. PMID: 39162485 Free PMC article.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: dao kh. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblentz C, Cohen AM, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Dibb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Monteblanco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, Spurgeon SE, Sweeney T, Swords RT, Thapa A, Thiel-Klare K, Traer E, Wagner J, Wilmot B, Wolf J, Wu G, Yates A, Zhang H, Cogle CR, Collins RH, Deininger MW, Hourigan CS, Jordan CT, Lin TL, Martinez ME, Pallapati RR, Pollyea DA, Pomicter AD, Watts JM, Weir SJ, Druker BJ, McWeeney SK, Tyner JW. Bottomly D, et al. Cancer Cell. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21. Cancer Cell. 2022. PMID: 35868306 Free PMC article.
42 results